Tempest Therapeutics Inc (TPST NASDAQ) stock market data APIs
$1.9333
0.02(1%)
as of May 11, 2026
Try our APIs with
free plan!
Tempest Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Prev. Close
1.9333
Open
1.9505
High
1.9855
Low
1.9069
52 wk Range
1.5-12.23
Market Cap
28 545 K
Shares Outstanding
14 344 K
EPS
-0.62
Beta
-1.685
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tempest Therapeutics Inc data using free add-ons & libraries
Get Tempest Therapeutics Inc Fundamental Data
Tempest Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -26 309 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Tempest Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-30
- EPS/Forecast: -0.62
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tempest Therapeutics Inc News
New
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-t...
New Strong Buy Stocks for April 10th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Escalade, Incorporated ESCA: This sporting goods company has seen the Zacks Consensus Estimate for its current year earnings i...
Tempest Therapeutics Secures Up To $6 Million To Advance Clinical Pipeline, Stock Plunges
(RTTNews) - Shares of Tempest Therapeutics (TPST) moved lower after the company announced it had entered into a securities purchase agreement for a private placement of up to $6 million. The financin...
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Cincinnati Children’s Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned ...
Get Tempest Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
